Intrathecal Administration of Double Checkpoint Inhibition in Combination with Pemetrexed in Patients with Leptomeningeal Metastasis: a Monocentric Phase I/II
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Pemetrexed (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2025 to 1 Sep 2025.
- 26 Mar 2025 Status changed from not yet recruiting to recruiting.
- 11 Feb 2025 New trial record